Bicknell R
Imperial Cancer Research Fund, John Radcliffe Hospital, Oxford, U.K.
Ann Oncol. 1994;5 Suppl 4:45-50. doi: 10.1093/annonc/5.suppl_4.s45.
Recent advances in our understanding of the process by which tumours elicit an angiogenic response, and of differences between normal and tumour vasculature, are revealing new strategies for anticancer therapy. The current status of anti-angiogenic therapy, together with approaches to targeting tumour vasculature, is reviewed. In particular, the advantages of using tumour vasculature as a target for anticancer gene therapy are outlined.
我们对肿瘤引发血管生成反应的过程以及正常血管与肿瘤血管差异的理解取得了新进展，这正揭示出抗癌治疗的新策略。本文综述了抗血管生成治疗的现状以及靶向肿瘤血管的方法。特别概述了将肿瘤血管作为抗癌基因治疗靶点的优势。
